|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Argatroban#Structure]] |
| {{Argatroban}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Description==
| |
| | |
| Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5-[(aminoiminomethyl) amino]-1-oxo-2[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2- piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
| |
| | |
| The molecular formula of argatroban is C23H36N6O5S•H2O. Its molecular weight is 526.66 g/mol. The structural formula is:
| |
| {|
| |
| | [[File:Argatroban_09.png|thumb|600px]]
| |
| |}
| |
| Argatroban Injection is a sterile, non-pyrogenic, clear, colorless to pale yellow, aqueous solution. It is supplied in a single use, clear glass vial containing 50 mg of argatroban in 50 mL solution. Each mL, contains 1 mg argatroban, 2 mg lactobionic acid, 2 mg L-methionine USP, 8 mg sodium chloride USP, and sodium hydroxide NF (for pH adjustment) in water for injection USP. The pH of the solution is approximately 8.8. | |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==Reference==
| |
| | |
| {{reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Hematology]]
| |
| [[Category:Drugs]]
| |